Bessemer Group Inc. Has $240,000 Stock Position in Sanofi (NASDAQ:SNY)

Bessemer Group Inc. increased its stake in shares of Sanofi (NASDAQ:SNY) by 570.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,339 shares of the company’s stock after buying an additional 3,692 shares during the period. Bessemer Group Inc.’s holdings in Sanofi were worth $240,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Lee Danner & Bass Inc. acquired a new position in Sanofi during the 4th quarter worth about $31,000. UMB Bank n.a. lifted its position in Sanofi by 30.7% during the 1st quarter. UMB Bank n.a. now owns 1,124 shares of the company’s stock valued at $62,000 after purchasing an additional 264 shares during the period. AdvisorNet Financial Inc lifted its position in Sanofi by 16.4% during the 1st quarter. AdvisorNet Financial Inc now owns 1,613 shares of the company’s stock valued at $89,000 after purchasing an additional 227 shares during the period. ORG Wealth Partners LLC acquired a new position in Sanofi during the 1st quarter valued at about $91,000. Finally, Thurston Springer Miller Herd & Titak Inc. lifted its position in Sanofi by 989.0% during the 1st quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,884 shares of the company’s stock valued at $104,000 after purchasing an additional 1,711 shares during the period. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Stock Performance

Shares of SNY stock opened at $49.31 on Thursday. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.37 and a quick ratio of 0.69. The stock has a market cap of $120.93 billion, a PE ratio of 17.61, a price-to-earnings-growth ratio of 1.01 and a beta of 0.48. The stock has a 50-day moving average of $50.77 and a 200-day moving average of $52.03. Sanofi has a one year low of $45.80 and a one year high of $60.12.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The company had revenue of $10.41 billion during the quarter, compared to analysts’ expectations of $9.79 billion. During the same period in the prior year, the business posted $1.78 EPS. Sanofi’s revenue was down 11.0% on a year-over-year basis. As a group, sell-side analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which was paid on Thursday, June 12th. Investors of record on Friday, May 9th were paid a dividend of $2.0369 per share. This represents a yield of 3.1%. This is a boost from Sanofi’s previous annual dividend of $1.48. The ex-dividend date was Friday, May 9th. Sanofi’s dividend payout ratio is presently 57.14%.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of Sanofi in a research report on Friday, March 21st. They set a “neutral” rating and a $65.00 target price on the stock. Hsbc Global Res upgraded shares of Sanofi to a “strong-buy” rating in a research report on Monday, April 28th. Barclays restated an “overweight” rating on shares of Sanofi in a research report on Wednesday. BNP Paribas initiated coverage on shares of Sanofi in a research report on Tuesday, April 15th. They set an “outperform” rating and a $65.00 target price on the stock. Finally, Guggenheim reaffirmed a “buy” rating on shares of Sanofi in a research note on Tuesday, June 3rd. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $61.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.